Seroconversion with Japanese encephalitis vaccine via intradermal route in healthy individuals

Not Applicable

Completed

• Conditions: Japanese encephalitis; Infection - Other infectious diseases; Neurological - Other neurological disorders

• Registration Number: ACTRN12621000024842
• Lead Sponsor: The University of Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-14
• Study Completion: 2022-07-18
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

Able to give written informed consent after all aspects of the protocol have been explained.
Between 18 and 45 years of age.
No prior history of Japanese encephalitis vaccination.
No serious uncontrolled medical conditions (as determined by a travel medicine doctor).

Exclusion Criteria

Previous Japanese encephalitis vaccine.
Previous dengue and/or yellow fever vaccine, or planning to have any of these vaccines during the next two months.
Live vaccine in the month prior, or planning to have during the next two months.
Contraindication for Japanese encephalitis vaccine.
Contraindication for live vaccines.
History of dengue fever.
Taking medications (e.g. TNF inhibitors, methotrexate, or steroids) or medical conditions that impair the normal functioning of the immune system.
Pregnancy or planning pregnancy.
Breastfeeding.
Lived in Japanese encephalitis risk area for more than a year.
Travelling or planning to travel to areas of high risk for Japanese encephalitis within the next two months.

Study & Design

• Study Type: Interventional
• Study Design: Not specified